<prompt> Following statements are true about Afrezza exceptUsed for both Type I and Type II diabetesSubstitute for long acting insulinIt is a rapid acting insulinUsed as inhaled insulin formulation and techno-sphere technology  <response>: Afrezza Approved in 2014 For both Type I and Type II diabetes Available as single-use caridges of 4 and 8 units Is rapid acting inhaled insulin, administered at the beginning of each meal Inhaled insulin formulation 2.5mm and technosphere technology Remember: Afrezza Not a substitute for long acting insulin Must be used in combination with long acting insulin in Type I diabetes Not recommended for treatment of Diabetic Ketoacidosis or in patient who smoke. Use restricted in Asthma Active lung cancer Chronic Obstructive Pulmonary Disease 